Updating the Management of the Dental Patient at Risk for Osteonecrosis of the Jaw Bone (ONJ) While Taking Bisphosphonates or Denosumab (Prolia®) - Latest Reports from the American Dental Association
Clinical Update From LexiComp
The American Dental Association
(ADA) has released two reports which update previous reports on the
management of the dental patient at risk for osteonecrosis of the jaw
bone (ONJ) while taking bisphosphonates. The first is a 47-page report,
dated December 2011 and posted on the ADA web site, entitled "Managing
the Care of Patients Receiving Antiresorptive Therapy for Prevention and
Treatment of Osteoporosis: Recommendations from the American Dental
Association Council on Scientific Affairs." The second report was
published as an executive summary on the same topic in the December 2011
issue of the Journal of the American Dental Association. Both
reports update a 2008 report on the management and care of patients
receiving oral bisphosphonate therapy, which was described in an earlier
newsletter by this author. This month's newsletter describes and
summarizes these latest reports.
|
Comments